2022
Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC
Olsen EA, Whittaker S, Willemze R, Pinter-Brown L, Foss F, Geskin L, Schwartz L, Horwitz S, Guitart J, Zic J, Kim YH, Wood GS, Duvic M, Ai W, Girardi M, Gru A, Guenova E, Hodak E, Hoppe R, Kempf W, Kim E, Lechowicz MJ, Ortiz-Romero P, Papadavid E, Quaglino P, Pittelkow M, Prince HM, Sanches JA, Sugaya M, Vermeer M, Zain J, Knobler R, Stadler R, Bagot M, Scarisbrick J. Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC. Blood 2022, 140: 419-437. PMID: 34758074, PMCID: PMC9353153, DOI: 10.1182/blood.2021012057.Peer-Reviewed Original ResearchConceptsPrimary cutaneous lymphomasNon-Hodgkin lymphomaCutaneous lymphomasMycosis fungoides/Sézary syndromeCutaneous Lymphoma Task ForceInvestigator-initiated trialPotential prognostic factorsNumber of patientsClinical trial guidelinesClinical trial designExtracutaneous diseaseSézary syndromePrognostic factorsTreatment of cancerTrials guidelinesClinical trialsComparative efficacyTrial designNumber of subtypesEuropean OrganizationNew treatmentsLymphomaResponse criteriaTherapeutic agentsStudy designTreatment at high-volume facilities is associated with improved overall survival for patients with cutaneous B-cell lymphoma
Cheraghlou S, Ugwu N, Girardi M. Treatment at high-volume facilities is associated with improved overall survival for patients with cutaneous B-cell lymphoma. Journal Of The American Academy Of Dermatology 2022, 88: 203-205. PMID: 35476920, DOI: 10.1016/j.jaad.2022.04.032.Peer-Reviewed Original ResearchCorrection to: The PROVe Study: US Real-World Experience with Chlormethine/Mechlorethamine Gel in Combination with Other Therapies for Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma
Kim EJ, Guitart J, Querfeld C, Girardi M, Musiek A, Akilov OE, Angello JT, Bailey WL, Geskin LJ. Correction to: The PROVe Study: US Real-World Experience with Chlormethine/Mechlorethamine Gel in Combination with Other Therapies for Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma. American Journal Of Clinical Dermatology 2022, 23: 425-425. PMID: 35292936, PMCID: PMC9172872, DOI: 10.1007/s40257-022-00676-1.Peer-Reviewed Original Research
2020
110 RNA expression analysis in stage IVA-B cutaneous T-cell lymphoma to identify novel biomarkers of prognosis and diagnosis
Mirza F, Yumeen S, Lewis J, King A, Kim S, Carlson K, Foss F, Girardi M. 110 RNA expression analysis in stage IVA-B cutaneous T-cell lymphoma to identify novel biomarkers of prognosis and diagnosis. Journal Of Investigative Dermatology 2020, 140: s13. DOI: 10.1016/j.jid.2020.03.113.Peer-Reviewed Original ResearchUnited States Cutaneous Lymphoma Consortium recommendations for treatment of cutaneous lymphomas during the COVID-19 pandemic
Zic J, Ai W, Akilov O, Carter J, Duvic M, Foss F, Girardi M, Gru A, Kim E, Musiek A, Olsen E, Schieke S, Shinohara M, Zain J, Geskin L. United States Cutaneous Lymphoma Consortium recommendations for treatment of cutaneous lymphomas during the COVID-19 pandemic. Journal Of The American Academy Of Dermatology 2020, 83: 703-704. PMID: 32305443, PMCID: PMC7161526, DOI: 10.1016/j.jaad.2020.04.049.Peer-Reviewed Original ResearchMeSH KeywordsAntibiotics, AntineoplasticAntineoplastic Agents, ImmunologicalBetacoronavirusChemoradiotherapyCoronavirus InfectionsCOVID-19Hematopoietic Stem Cell TransplantationHome Care Services, Hospital-BasedHumansLymphoma, T-Cell, CutaneousMycosis FungoidesPandemicsPatient SelectionPhotopheresisPneumonia, ViralRisk AssessmentSARS-CoV-2Severity of Illness IndexSezary SyndromeSkin NeoplasmsTelemedicineUltraviolet TherapyUnited StatesReal-world experience with mechlorethamine gel in patients with mycosis fungoides-cutaneous lymphoma: Preliminary findings from a prospective observational study
Kim EJ, Geskin L, Guitart J, Querfeld C, Girardi M, Musiek A, Mink DR, Williams MJ, Angello JT, Bailey WL. Real-world experience with mechlorethamine gel in patients with mycosis fungoides-cutaneous lymphoma: Preliminary findings from a prospective observational study. Journal Of The American Academy Of Dermatology 2020, 83: 928-930. PMID: 32089294, DOI: 10.1016/j.jaad.2019.12.070.Peer-Reviewed Original Research
2019
Effect of leucovorin administration on mucositis and skin reactions in patients with peripheral T-cell lymphoma or cutaneous T-cell lymphoma treated with pralatrexate*
Foss FM, Parker TL, Girardi M, Li A. Effect of leucovorin administration on mucositis and skin reactions in patients with peripheral T-cell lymphoma or cutaneous T-cell lymphoma treated with pralatrexate*. Leukemia & Lymphoma 2019, 60: 2927-2930. PMID: 31119966, DOI: 10.1080/10428194.2019.1612061.Peer-Reviewed Original ResearchConceptsPeripheral T-cell lymphomaCutaneous T-cell lymphomaT-cell lymphomaIncidence of mucositisAddition of leucovorinSkin reactionsLeucovorin administrationMucositis incidenceMucositis occurrenceDisease stabilizationAdverse eventsClinical responseCTCL patientsPoor prognosisLeucovorinMucositisPatientsResponse rateLymphomaPralatrexateIncidenceEfficacyPrognosisDosingAdministration108 Efficacy and quality of life (QoL) in patients with mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL) treated with chlormethine gel and other therapies: results from the PROVe study
Kim E, Geskin L, Querfeld C, Girardi M, Mink D, Williams M, Angello J, Bailey W. 108 Efficacy and quality of life (QoL) in patients with mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL) treated with chlormethine gel and other therapies: results from the PROVe study. European Journal Of Cancer 2019, 119: s39. DOI: 10.1016/s0959-8049(19)30618-5.Peer-Reviewed Original Research
2018
Clinical Activity of Pralatrexate in Patients With Cutaneous T-Cell Lymphoma Treated With Varying Doses of Pralatrexate
Foss FM, Parker TL, Girardi M, Li A. Clinical Activity of Pralatrexate in Patients With Cutaneous T-Cell Lymphoma Treated With Varying Doses of Pralatrexate. Clinical Lymphoma Myeloma & Leukemia 2018, 18: e445-e447. PMID: 30181105, DOI: 10.1016/j.clml.2018.06.020.Peer-Reviewed Original Research
2017
Primary cutaneous aggressive epidermotropic cytotoxic CD8+ T‐cell lymphoma: long‐term remission after brentuximab vedotin
Cyrenne BM, Subtil A, Girardi M, Foss F. Primary cutaneous aggressive epidermotropic cytotoxic CD8+ T‐cell lymphoma: long‐term remission after brentuximab vedotin. International Journal Of Dermatology 2017, 56: 1448-1450. PMID: 29047111, DOI: 10.1111/ijd.13792.Peer-Reviewed Original Research
2014
CD4 + primary cutaneous small/medium-sized pleomorphic T-cell lymphoma: a retrospective case series and review of literature
James E, Sokhn JG, Gibson JF, Carlson K, Subtil A, Girardi M, Wilson LD, Foss F. CD4 + primary cutaneous small/medium-sized pleomorphic T-cell lymphoma: a retrospective case series and review of literature. Leukemia & Lymphoma 2014, 56: 951-957. PMID: 24996443, DOI: 10.3109/10428194.2014.938331.Peer-Reviewed Original ResearchConceptsT-cell lymphomaSmall/medium-sized pleomorphic T-cell lymphomaPleomorphic T-cell lymphomaPCSM-TCLSystemic involvementCase seriesWorld Health Organization-European OrganizationIndolent T-cell lymphomaRare T-cell lymphomaLocalized radiationRetrospective case seriesCD7 lossReview of literatureComplete remissionCytotoxic chemotherapyMedian ageFavorable prognosisRetrospective studyTreatment of cancerExcisional biopsyCD4Local modalitiesPatientsLymphomaInvasive features
2013
Induction of monocyte-to-dendritic cell maturation by extracorporeal photochemotherapy: Initiation via direct platelet signaling
Durazzo TS, Tigelaar RE, Filler R, Hayday A, Girardi M, Edelson RL. Induction of monocyte-to-dendritic cell maturation by extracorporeal photochemotherapy: Initiation via direct platelet signaling. Transfusion And Apheresis Science 2013, 50: 370-378. PMID: 24360371, PMCID: PMC4167725, DOI: 10.1016/j.transci.2013.11.008.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaExtracorporeal photochemotherapyDendritic cellsDendritic cell maturationT-cell lymphomaInduction of monocytesEvidence of inductionPost-capillary venulesDC maturationCell lymphomaClinical actionsCell maturationPlatelet signalingMonocytesPhotochemotherapyReceptor-ligand interactionsNovel mechanismInductionPhysiological inductionMaturationPrevious studiesLymphomaTherapyVenules
2012
Immunotherapy for Cutaneous T-Cell Lymphoma
Modi B, Foss F, Edelson R, Girardi M. Immunotherapy for Cutaneous T-Cell Lymphoma. Contemporary Hematology 2012, 307-316. DOI: 10.1007/978-1-62703-170-7_18.Peer-Reviewed Original ResearchCutaneous T-cell lymphomaT-cell lymphomaToll-like receptor agonistsEffector T cell activityImmune effector mechanismsT cell activityGoal of therapyCytokine-based therapiesHistone deacetylase inhibitorsClinical responseMost patientsImmunotherapeutic approachesInterleukin-12Receptor agonistEffector mechanismsInterleukin-2Therapeutic approachesImmune functionDeacetylase inhibitorsTherapyCTCLPatientsLymphomaAttractive targetImmunotherapy
2011
Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer
Olsen EA, Whittaker S, Kim YH, Duvic M, Prince HM, Lessin SR, Wood GS, Willemze R, Demierre MF, Pimpinelli N, Bernengo MG, Ortiz-Romero PL, Bagot M, Estrach T, Guitart J, Knobler R, Sanches JA, Iwatsuki K, Sugaya M, Dummer R, Pittelkow M, Hoppe R, Parker S, Geskin L, Pinter-Brown L, Girardi M, Burg G, Ranki A, Vermeer M, Horwitz S, Heald P, Rosen S, Cerroni L, Dreno B, Vonderheid EC. Clinical End Points and Response Criteria in Mycosis Fungoides and Sézary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. Journal Of Clinical Oncology 2011, 29: 2598-2607. PMID: 21576639, PMCID: PMC3422534, DOI: 10.1200/jco.2010.32.0630.Peer-Reviewed Original ResearchConceptsMF/Sézary syndromeSézary syndromeMycosis fungoidesClinical trialsEnd pointResponse criteriaUnited States Cutaneous Lymphoma ConsortiumCutaneous T-cell lymphomaCutaneous Lymphoma Task ForceInvestigator-initiated clinical trialsPotential disease manifestationsClinical end pointsEarly mycosis fungoidesT-cell lymphomaUniform stagingCutaneous lymphomasLymph nodesTreatment of cancerHodgkin's lymphomaDisease manifestationsConsensus statementConsensus recommendationsVisceral organsEuropean OrganizationLymphoma
2010
More or Less: Copy Number Alterations in Mycosis Fungoides
Lin WM, Girardi M. More or Less: Copy Number Alterations in Mycosis Fungoides. Journal Of Investigative Dermatology 2010, 130: 926-928. PMID: 20231832, DOI: 10.1038/jid.2009.370.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaMycosis fungoidesSkin-homing T cellsNon-Hodgkin lymphomaT-cell lymphomaCutaneous plaquesLymph nodesTumor involvementT cellsSkin diseasesLymphomaHeterogeneous groupGenetic alterationsCommon formGenomic DNA alterationsFungoidesNumber alterationsDNA alterationsAlterationsPrognosisMalignancyPathogenesisPlaquesDiseaseBlood
2008
Cutaneous T cell lymphoma: translating immunobiology into therapeutic opportunities.
Berger CL, Heald P, Girardi M, Edelson RL. Cutaneous T cell lymphoma: translating immunobiology into therapeutic opportunities. Giornale Italiano Di Dermatologia E Venereologia 2008, 143: 43-54. PMID: 18833050.Peer-Reviewed Original ResearchMeSH KeywordsAdrenal Cortex HormonesAnimalsAntibodies, MonoclonalAntineoplastic Combined Chemotherapy ProtocolsApoptosisBexaroteneClone CellsCytokinesDendritic CellsDiphtheria ToxinGene Expression Regulation, NeoplasticHumansImmunophenotypingInterleukin-2Lymphoma, T-Cell, CutaneousMiceNeoplastic Stem CellsPhotopheresisPUVA TherapyRecombinant Fusion ProteinsTetrahydronaphthalenesT-Lymphocyte SubsetsT-Lymphocytes, RegulatoryConceptsCutaneous T-cell lymphomaSheep red blood cellsT-cell lymphomaNew therapeutic approachesBasic science techniquesRed blood cellsClinical featuresTherapeutic optionsT lymphocytesCell lymphomaTherapeutic approachesClinical practiceImmune systemMalignant cellsTherapeutic opportunitiesBlood cellsPatientsImmunobiologyDiseaseMolecular demonstrationCurrent understandingCellsLymphomaLymphocytesImmunology
2000
Cutaneous T-cell lymphoma: pathogenesis and treatment.
Girardi M, Edelson RL. Cutaneous T-cell lymphoma: pathogenesis and treatment. Oncology 2000, 14: 1061-70; discussion 1070-4, 1076. PMID: 10929591.Peer-Reviewed Original ResearchConceptsCutaneous T-cell lymphomaSkin immune systemImmune systemT cellsManagement of CTCLCutaneous T-cellMemory T cellsT helper cellsT-cell lymphomaSelective adhesion moleculeLymph nodesClinical spectrumPeripheral bloodCutaneous pathogensMajor subtypesPathogenesisAdhesion moleculesLymphomaDistinctive subsetTreatmentNormal functioningCellsBetter understandingImmunosurveillanceMalignancyCUTANEOUS T-CELL LYMPHOMA AND CUTANEOUS GRAFT-VERSUS-HOST DISEASE Two Indications for Photopheresis in Dermatology
Girardi M, Heald PW. CUTANEOUS T-CELL LYMPHOMA AND CUTANEOUS GRAFT-VERSUS-HOST DISEASE Two Indications for Photopheresis in Dermatology. Dermatologic Clinics 2000, 18: 417-423. PMID: 10943537, DOI: 10.1016/s0733-8635(05)70190-x.Peer-Reviewed Original Research
1999
Extracorporeal photochemotherapy in human and murine graft-versus-host disease
Girardi M, McNiff J, Heald P. Extracorporeal photochemotherapy in human and murine graft-versus-host disease. Journal Of Dermatological Science 1999, 19: 106-113. PMID: 10098701, DOI: 10.1016/s0923-1811(98)00066-8.Peer-Reviewed Original Research